Notes to Consolidated Financial Statements
November 30, 2012 and 2011
Note 1 Nature of Operations
BioPower Corporation (“BioPower”
or “the Company”) was incorporated in the State of Florida on September 13, 2010. On January 5, 2011, the Company re-domiciled
to Nevada and formed BioPower Operations Corporation, a Nevada corporation. On January 6, 2011, the shareholders of BioPower Corporation
contributed their shares of BioPower Corporation to BioPower Operations Corporation and BioPower Corporation became a wholly-owned
subsidiary.
The Company intends to grow biomass crops
and will use milling operations to produce oils, biofuels, electricity and other biomass products. The Company also intends to
license, joint venture and build facilities by utilizing its license for the patented technology that converts, poultry, hog, human
and sugar wastes to cellulosic ethanol, fertilizer and other products.
On June 8, 2012, the Company's Chief Executive
Officer contributed 100% of his member interest in FTZ Exchange, LLC, (“FTZ”) which became a 100% wholly subsidiary
to the Company for no consideration. On the date of contribution, FTZ has a 50-50 joint venture, known as, the Qx Health Exchange
(“QX”) and a wholly-owned subsidiary, called FTZ Energy Exchange Corporation, which intends to launch an energy exchange.
FTZ is a licensing company which intends to use its business know-how to develop multiple distribution channels, known as exchanges,
for the sale of various products and services. On the date of contribution, FTZ had a nominal net book value.
The Company’s fiscal year end is
November 30.
Note 2 Restatement of Previously
Issued 2012 Quarterly Financial Statements
The Audit Committee of the
Company’s Board of Directors previously determined that that Company’s unaudited interim consolidated financial
statements for the quarters ended February 29, May 31, and August 31, 2012 (“Relevant Periods”) should no longer
be relied upon. The Company filed amendments to its quarterly reports on Form 10-Q for the Relevant Periods on August 12,
2013 as a result of management’s determination that the Company’s accounting treatment pertaining to (a) revenue
recognition on its non-operating consulting advisory agreement executed in February 2012, (b) common stock authorized but not
issued and (c) the loan cost in connection with a third party loan arrangement should be modified. Additionally, management
included disclosure of the impact of the restatements in a footnote for the affected periods in the Forms 10-Q for the
quarters ended February 28, 2013, May 31, 2013 and August 13, 2013. The consolidated financial statements for the year ended
November 30, 2012 do not require restatement.
Note 3 Summary of Significant Accounting
Policies
Principles of Consolidation
All inter-company accounts and transactions have been eliminated
in consolidation.
BioPower Operations Corporation and Subsidiaries
(A Development Stage Company)
Notes to Consolidated Financial Statements
November 30, 2012 and 2011
Development Stage
The Company's consolidated financial statements
are presented as those of a development stage enterprise. Activities during the development stage primarily include negotiating
distribution agreements and marketing the territory for distribution outlets for the product. The Company, while seeking to implement
its business plan, will look to obtain additional debt and/or equity related funding opportunities. The Company has not generated
any revenues from its planned and principal operations since inception.
Risks and Uncertainties
The Company intends to operate in an industry
that is subject to rapid change. The Company's operations will be subject to significant risk and uncertainties including financial,
operational, technological, regulatory and other risks, including the potential risk of business failure. Also, see Note 4 regarding
going concern matters.
Use of Estimates
The preparation of financial statements
in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the reporting period.
Such estimates and assumptions for the
periods ended November 30, 2012 and 2011, affect, among others, the following:
|
·
|
estimated fair value of share based payments,
|
|
·
|
estimated carrying value, useful lives and related impairment of equipment
and intangible assets; and
|
|
·
|
estimated valuation allowance for deferred tax assets, due to continuing
and expected future losses
|
Making estimates requires management to
exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or
set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate
could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly
from estimates.
Cash
The Company considers all highly liquid
instruments purchased with a maturity of three months or less and money market accounts to be cash equivalents. The Company had
no cash equivalents at November 30, 2012 and 2011.
Marketable
Securities
(A) Classification
of Securities
At the time of acquisition, a security
is designated as held-to-maturity (“HTM”), available-for-sale (“AFS”), or trading, which depends on ability
and intent to hold such security to maturity. Securities classified as trading and AFS are reported at fair value, while securities
classified as HTM are reported at amortized cost.
Any unrealized gains and losses are reported
as other comprehensive income (loss). Realized gains (losses) are computed on a specific identification basis and are recorded
in net capital gains (losses) on investments in the combined consolidated statements of operations.
During 2012, the Company sold 10,000,000
shares of their AFS securities, having a cost basis of $169,000 (0.0169/share), for proceeds of $52,560, resulting in a loss on
sale of $116,440. In addition, the Company was required to pay 500,000 shares in AFS securities, having a cost basis of $8,450
and FMV of $6,250 as a collection fee, which resulted in an additional loss of $2,200. See Note 13.
BioPower Operations Corporation and Subsidiaries
(A Development Stage Company)
Notes to Consolidated Financial Statements
November 30, 2012 and 2011
The Company’s cost basis in AFS was
as follows:
|
|
Amount
|
|
|
Shares
|
|
AFS Acquired – February 2012
|
|
$
|
253,500
|
|
|
|
15,000,000
|
|
Sales in 2012 – at cost
|
|
|
(169,000
|
)
|
|
|
(10,000,000
|
)
|
Collection fee
|
|
|
(8,450
|
)
|
|
|
(500,000
|
)
|
Balance – November 30, 2012
|
|
$
|
76,050
|
|
|
|
4,500,000
|
|
The composition of the Company’s
investments at November 30, 2012, classified as current assets, is as follows:
|
|
Cost
|
|
|
Fair Value
|
|
|
Unrealized Loss
|
|
Common stock – public company
|
|
$
|
76,050
|
|
|
$
|
38,250
|
|
|
$
|
37,800
|
|
Total available for sale securities
|
|
$
|
76,050
|
|
|
$
|
38,250
|
|
|
$
|
37,800
|
|
Investment income (loss) for the year ended
November 30, 2012 and 2011 is as follows:
|
|
2012
|
|
|
2011
|
|
|
|
|
|
|
|
|
Gross realized losses from sale of available for sale securities
|
|
$
|
(118,640
|
)
|
|
$
|
-
|
|
Net unrealized holding gain (loss)
|
|
|
(37,800
|
)
|
|
|
-
|
|
Net investment income (loss)
|
|
$
|
(156,440
|
)
|
|
$
|
-
|
|
The Company
has a 100% concentration on one publicly traded stock.
(B) Impairment
The Company reviews its equity investment
portfolio for any unrealized losses that would be deemed other-than-temporary and require the recognition of an impairment loss
in income. If the cost of an investment exceeds its fair value, the Company evaluates, among other factors, general market conditions,
the duration and extent to which the fair value is less than cost, and the Company’s intent and ability to hold the investments.
Management also considers the type of security, related-industry and sector performance, as well as published investment ratings
and analyst reports, to evaluate its portfolio. Once a decline in fair value is determined to be other than temporary, an impairment
charge is recorded and a new cost basis in the investment is established. If market, industry, and/or investee conditions deteriorate,
the Company may incur future impairments. At November 30, 2012, no such impairments were recorded.
BioPower Operations Corporation and Subsidiaries
(A Development Stage Company)
Notes to Consolidated Financial Statements
November 30, 2012 and 2011
Equipment
Equipment is stated at cost, less accumulated
depreciation computed on a straight-line basis over the estimated useful lives. Maintenance and repairs are charged to operations
when incurred. Betterments and renewals are capitalized when deemed material. When equipment is sold or otherwise
disposed of, the asset account and related accumulated depreciation account are relieved, and any gain or loss is included in operations.
Equipment is reviewed for impairment whenever
events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. There were
no impairment charges taken during the periods ended November 30, 2012 and 2011.
Intangible Assets
Identifiable intangible assets with finite
lives are amortized over their estimated useful lives and are reviewed for impairment if indicators of potential impairment exist.
See Notes 9(c) and 10.
Investment in Joint Venture
FTZ has entered into a Joint Venture with
QX, a third party, to engage in the business of becoming an independent medical & health network for hospitals, physicians,
outpatient and urgent care centers, dental care, vision care, insurance companies, alternative medicine, medical tourism, pharmaceutical
companies, vendors and patients.
FTZ owns fifty percent of the QX joint
venture and will record its investment on the equity basis of accounting. The Company’s proportionate share of expenses incurred
by the Joint Venture will be charged to the statement of operations and adjusted against the Investment in Joint Venture. Losses
from the Joint Venture are only recognized until the investment in the Joint Venture is reduced to zero. Losses in excess of the
investment must be restored from future profits before the Company can recognize its proportionate share of profits.
As of November 30, 2012, the Joint Venture
had no activity.
Convertible debt,
Beneficial
Conversion Feature and Debt Discount
For conventional convertible debt where
the rate of conversion is below market value at the date of the agreement, the Company records a “beneficial conversion feature”
(“BCF”) and related debt discount.
When the Company records a BCF, the relative
fair value of the BCF would be recorded as a debt discount against the face amount of the respective debt instrument. The discount
would be amortized to interest expense over the life of the debt. When a conversion of the underlying debt occurs, a proportionate
share of the unamortized amounts is immediately expensed.
BioPower Operations Corporation and Subsidiaries
(A Development Stage Company)
Notes to Consolidated Financial Statements
November 30, 2012 and 2011
Derivative Liabilities
Fair value accounting requires bifurcation
of embedded derivative instruments such as conversion features in convertible debt or equity instruments, and measurement of their
fair value for accounting purposes. In determining the appropriate fair value, the Company expects to use the Black-Scholes option-pricing
model. In assessing the convertible debt instruments, management would determine if the convertible debt host instrument is conventional
convertible debt and further if there is a beneficial conversion feature requiring measurement. If the instrument is not considered
conventional convertible debt, the Company will continue its evaluation process of these instruments as derivative financial instruments.
Once determined, derivative liabilities
are adjusted to reflect fair value at each reporting period end, with any increase or decrease in the fair value being recorded
in results of operations as an adjustment to fair value of derivatives. In addition, the fair value of freestanding derivative
instruments such as warrants, are also valued using the Black-Scholes option-pricing model.
Share-based payments
The Company recognizes all forms of share-based
payments, including stock option grants, warrants, and restricted stock grants, at their fair value on the grant date, which are
based on the estimated number of awards that are ultimately expected to vest.
Share based payments, excluding restricted
stock, are valued using a Black-Scholes option pricing model. Share based payment awards issued to non-employees for services
rendered are recorded at either the fair value of the services rendered or the fair value of the share-based payment, whichever
is more readily determinable.
The grants are amortized on a straight-line
basis over the requisite service periods, which is generally the vesting period . If an award is granted, but vesting does not
occur, any previously recognized compensation cost is reversed in the period related to the termination of service.
When computing fair value, the Company
may consider the following variables:
|
●
|
The risk-free interest rate assumption is based on the U.S. Treasury yield for a period consistent
with the expected term of the option in effect at the time of the grant.
|
|
●
|
The Company has not paid any dividends on common stock since inception and does not anticipate
paying dividends on its common stock in the near future.
|
|
●
|
The expected option term is computed using the “simplified” method as permitted under
the provisions of Staff Accounting Bulletin (“SAB”) 110.
|
BioPower Operations Corporation and Subsidiaries
(A Development Stage Company)
Notes to Consolidated Financial Statements
November 30, 2012 and 2011
|
●
|
The expected volatility is based on the historical volatility of the Company’s common stock,
based on the daily quoted closing trading prices.
|
|
●
|
The forfeiture rate is based on the historical forfeiture rate for unvested stock options.
|
As of November 30, 2012, all shares not
yet issued are included as a component of common stock payable.
Earnings per share
Basic earnings (loss) per share is computed
by dividing net income (loss) by weighted average number of shares of common stock outstanding during each period. Diluted earnings
(loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock, common stock
equivalents and potentially dilutive securities outstanding during the period. The Company does not include shares not yet issued
that were included as a component of common stock payable in the earnings per share calculation.
Since the Company reflected a net loss
in 2012 and 2011, considering any common stock equivalents, if exercisable, would have been anti-dilutive. A separate computation
of diluted earnings (loss) per share is not presented.
The Company has the following potential
common stock equivalents at November 30, 2012 and 2011:
|
|
November 30,
2012
|
|
|
November 30,
2011
|
|
|
|
|
|
|
|
|
Warrants (1)
|
|
|
-
|
|
|
|
1,000,000
|
|
Convertible debt (2)
|
|
|
-
|
|
|
|
120,000
|
|
Total common stock equivalents
|
|
|
-
|
|
|
|
1,120,000
|
|
(1) On January 11, 2012, the 1,000,000 warrants expired unexercised.
(2) As of November 30, 2012, the convertible notes matured and
were reclassified to demand notes.
Also see Note 8.
Income Taxes
Provisions for income taxes are calculated
based on reported pre-tax earnings and current tax law.
Significant judgment is required in determining
income tax provisions and evaluating tax positions. The Company periodically assesses its liabilities and contingencies for all
periods that are currently open to examination or have not been effectively settled based on the most current available information.
When it is not more likely than not that a tax position will be sustained, the Company records its best estimate of the resulting
tax liability and any applicable interest and penalties in the financial statements.
BioPower Operations Corporation and Subsidiaries
(A Development Stage Company)
Notes to Consolidated Financial Statements
November 30, 2012 and 2011
Deferred tax assets and liabilities are
recorded for temporary differences between the tax basis of assets and liabilities and their reported amounts in the financial
statements using statutory rates in effect for the year in which the differences are expected to reverse. The Company presents
the tax effects of these deferred tax assets and liabilities separately for each major tax jurisdiction.
The effect on deferred tax assets and liabilities
of a change in tax rates is recognized in the results of operations in the period that the changes are enacted. The Company records
a valuation allowance to reduce deferred tax assets when it is more likely than not that some portion of the asset may not be realized.
The Company evaluates its deferred tax assets and liabilities on a periodic basis.
Deferred Revenue
Deferred revenue represents revenues that
were received, but not earned as of November 30, 2012. This is composed of revenues for advisory fees that were received in advance
and will be recorded as revenue when earned over the term of the consulting agreement. See Note 13.
Recent Accounting Pronouncements
There are no new accounting pronouncements
that are expected to have any material impact on the Company’s consolidated financial statements.
Reclassification
We have reclassified certain prior period
amounts to conform to the current period presentation. These reclassifications have no effect on the financial position or on the
results of operations or cash flows for the periods presented.
Note 4 Going Concern
As reflected in the accompanying consolidated
financial statements, the Company had a net loss of $1,274,448 and net cash used in operations of $242,190 for the year ended November
30, 2012; and a working capital deficit of $1,483,467 and a stockholders’ deficit of $1,478,046 at November 30, 2012. These
factors raise substantial doubt about the Company’s ability to continue as a going concern.
The ability of the Company to continue
as a going concern is dependent on Management's plans, which include potential asset acquisitions, mergers or business combinations
with other entities, further implementation of its business plan and continuing to raise funds through debt or equity financings.
The Company will likely rely upon related party debt or equity financing in order to ensure the continuing existence of the business.
The accompanying consolidated financial
statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities
in the normal course of business. These financial statements do not include any adjustments relating to the recovery of the recorded
assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.
Note 5 Equipment
At November 30, 2012 and 2011, equipment
consists of the following:
|
|
2012
|
|
|
2011
|
|
|
Estimated Useful Life
|
Computer Equipment
|
|
$
|
27,760
|
|
|
$
|
27,760
|
|
|
5 years
|
Less: Accumulated depreciation
|
|
|
(8,999
|
)
|
|
|
(3,447
|
)
|
|
|
Equipment, net
|
|
$
|
18,761
|
|
|
$
|
24,313
|
|
|
|
BioPower Operations Corporation and Subsidiaries
(A Development Stage Company)
Notes to Consolidated Financial Statements
November 30, 2012 and 2011
Note 6 Income Taxes
The Company recognizes deferred tax assets
and liabilities for both the expected impact of differences between the financial statements and the tax basis of assets and liabilities,
and for the expected future tax benefit to be derived from tax losses and tax credit carryforwards. The Company has
established a valuation allowance to reflect the likelihood of the realization of deferred tax assets.
The Company has a net operating loss carryforward
for tax purposes totaling approximately $560,000 at November 30, 2012, expiring through 2032. U.S. Internal Revenue Code Section
382 places a limitation on the amount of taxable income that can be offset by carryforwards after a change in control (generally
greater than a 50% change in ownership). Temporary differences, which give rise to a net deferred tax asset, are as
follows:
Significant deferred tax assets at November 30, 2012 and 2011
are approximately as follows:
|
|
2012
|
|
|
2011
|
|
Gross deferred tax assets:
|
|
|
|
|
|
|
|
|
Net operating loss carryforwards
|
|
$
|
229,000
|
|
|
$
|
56,000
|
|
Accrued payroll/taxes
|
|
|
340,000
|
|
|
|
169,000
|
|
Total deferred tax assets
|
|
|
569,000
|
|
|
|
225,000
|
|
Less: valuation allowance
|
|
|
(569,000
|
)
|
|
|
(225,000
|
)
|
Net deferred tax asset recorded
|
|
$
|
-
|
|
|
$
|
-
|
|
The valuation allowance at November 30,
2011 was approximately $225,000. The net change in valuation allowance during the period ended November 30, 2012 was an increase
of approximately $344,000.
In assessing the reliability of deferred
tax assets, management considers whether it is more likely than not that some portion or all of the deferred income tax assets
will not be realized. The ultimate realization of deferred income tax assets is dependent upon the generation of future
taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled
reversal of deferred income tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. Based
on consideration of these items, management has determined that enough uncertainty exists relative to the realization of the deferred
income tax asset balances to warrant the application of a full valuation allowance as of November 30, 2012.
BioPower Operations Corporation and Subsidiaries
(A Development Stage Company)
Notes to Consolidated Financial Statements
November 30, 2012 and 2011
The actual tax benefit differs from the expected tax benefit
for the period ended November 30, 2012 and 2011 (computed by applying the U.S. Federal Corporate tax rate of 34% to income before
taxes and 5.5% for State income taxes, a blended rate of 37.63%) approximately as follows:
|
|
2012
|
|
|
2011
|
|
Expected tax expense (benefit) - Federal
|
|
$
|
(410,000
|
)
|
|
$
|
(311,000
|
)
|
Expected tax expense (benefit) - State
|
|
|
(70,000
|
)
|
|
|
(53,000
|
)
|
Meals and Entertainment @50%
|
|
|
4,000
|
|
|
|
4,000
|
|
Impairment loss on license agreement
|
|
|
91,000
|
|
|
|
-
|
|
Stock/stock options/warrants issued for services
|
|
|
41,000
|
|
|
|
136,000
|
|
Change in valuation allowance
|
|
|
344,000
|
|
|
|
224,000
|
|
Actual tax expense (benefit)
|
|
$
|
-
|
|
|
$
|
-
|
|
Note 7 Notes Payable – Related
Parties
|
(A)
|
Period Ended November 30, 2010
|
During November 2010, the Company’s
Chief Executive Officer advanced $10,927. The loan bears interest at 4%, is unsecured and due on demand.
During November 2010, a Company Director
advanced $10,000. The loan bears interest at 4%, is unsecured and due on demand.
|
(B)
|
Year Ended November 30, 2011
|
During December 2010, a Company Director
advanced $506. The loan bears interest at 4%, is unsecured and due on demand.
During January 2011, the Company’s
Chief Executive Officer advanced $832. The loan bears interest at 4%, is unsecured and due on demand.
During January 2011, a Company Director
advanced $631. The loan bears interest at 4%, is unsecured and due on demand.
During February 2011, a Company Director
advanced $985. The loan bears interest at 4%, is unsecured and due on demand.
During May 2011, the Company repaid all
related party advances totaling $23,881.
During October 2011, the Company's former
President/Chief Operating Officer, advanced $25,000. The loan bears interest at 4%, is unsecured and due on demand. The lender
may convert the loan into 100,000 restricted shares of the Company at $0.25 per share. The Company has determined that this is
conventional convertible debt, with a BCF. See Note 8(C). As of November 30, 2012, this loan has been reflected as on demand payable
to a third party given the individual has resigned from his position as of August of 2012 and has made a demand for payment. Given
the Company’s inability to repay the note, the note is currently in default.
During November 2011, the Company's former
President/Chief Operating Officer until August 2012, advanced $5,000. The loan bears interest at 4%, is unsecured and due on demand.
The lender may convert the loan into 20,000 restricted shares of the Company at $0.25 per share. The Company has determined that
this is conventional convertible debt, with a BCF. See Note 8(C) As of November 30, 2012, this loan has been reflected on demand
payable to a third party given the individual has resigned from his position as of August of 2012 and has made a demand for payment.
Given the Company’s inability to repay the note, the note is currently in default.
As of November 30, 2011, the Company owed
$479 in accrued interest, which has been recorded as a component of accounts payable and accrued expenses.
BioPower Operations Corporation and Subsidiaries
(A Development Stage Company)
Notes to Consolidated Financial Statements
November 30, 2012 and 2011
|
(C)
|
Year Ended November 30, 2012
|
During February 2012, the Company’s
Chief Executive Officer advanced $2,500. The loan bears interest at 4%, is unsecured and due on demand.
During March 2012, the Company’s
Chief Executive Officer advanced $17,000. The loan bears interest at 4%, is unsecured and due on demand.
During April 2012, the Company’s
Chief Executive Officer advanced $9,000. The loan bears interest at 4%, is unsecured and due on demand.
During June 2012, the Company’s Chief
Executive Officer advanced $1,592. The loan is non-interest bearing, unsecured and due on demand. In October 2012, the Company
repaid an advance of $1,417 to its Chief Executive Officer.
During July 2012, the Company’s Chief
Executive Officer advanced $12,000. The loan bears interest at 4%, is unsecured and due on demand.
As of November 30, 2012, the Company owes
$854 in accrued interest, which has been recorded as a component of accounts payable and accrued expenses.
BioPower Operations Corporation and Subsidiaries
(A Development Stage Company)
Notes to Consolidated Financial Statements
November 30, 2012 and 2011
Note 8 Notes Payable and Convertible
Debt
(A) Year Ended November 30, 2012
During December 2011 and January 2012,
the Company’s former President, until August 2012, advanced $40,000. The loans bear interest at 4%, are unsecured and due
on demand. Originally, the lender had the option to convert the loan into 160,000 restricted shares of the Company at $0.25 per
share. As of November 30, 2012, the note has matured and demand has been made so the Company has reclassified this note as a demand
note.
During April 2012 and May 2012, a third
party investor advanced $50,000 due on July 31, 2012. The loan bears interest at 4% and is unsecured. The lender may convert the
loan into 200,000 restricted shares of the Company at $0.25 per share. On July 31, 2012, the notes maturity dates were extended
until November 30, 2012. On October 18, 2012, the third party investor converted the above $50,000 loan into 200,000 restricted
shares of the Company's common stock at $0.25/share. See Note 8(C). As of November 30, 2012, the 200,000 shares have not been issued
and are included in common stock payable.
During June 2012, a third party investor
advanced $1,000. The loan bears interest at 4%, is unsecured and due on demand. In June 2012, the Company repaid an advance of
$1,000 to a third party investor.
During July 2012, a third party investor
advanced $12,000. The loan bears interest at 4%, is unsecured and due on demand.
During October 2012, a third party investor
advanced $7,800. The loan bears interest at 4%, is unsecured and due on demand.
As of November 30, 2012, the Company owes
$3,674 in accrued interest, which has been recorded as a component of accounts payable and accrued expenses.
(B) Debt Discount
For the years ended November 30, 2012 and
November 30, 2011, the Company recorded debt discounts totaling of $90,000 and $30,000, respectively.
As a component of the computation for BCF,
the Company’s market price was determined based upon recent third party cash offerings at the date of issuance prior to February
2012 when the Company's stock began to trade.
The following is a summary of the Company’s
convertible debt discount at November 30, 2012 and November 30, 2011.
|
|
2012
|
|
|
2011
|
|
Debt Discount
|
|
$
|
120,000
|
|
|
|
(30,000
|
)
|
Amortization of Debt Discount
|
|
|
(120,000
|
)
|
|
|
3,571
|
|
Remaining debt discount
|
|
$
|
-
|
|
|
$
|
(26,429
|
)
|
The following is a summary of the Company's convertible debt
at November 30, 2012 and November 30, 2011.
|
|
2012
|
|
|
2011
|
|
Convertible Debt
|
|
$
|
120,000
|
|
|
$
|
30,000
|
|
Debt Discount
|
|
|
(120,000
|
)
|
|
|
(30,000
|
)
|
Amortization of Debt Discount
|
|
|
120,000
|
|
|
|
3,571
|
|
Conversion of Debt into 200,000 shares of common stock to be issued
|
|
|
(50,000
|
)
|
|
|
-
|
|
Reclassification of Convertible Note to Demand Note - former related party
|
|
|
(70,000
|
)
|
|
|
-
|
|
Convertible Debt – Net
|
|
$
|
-
|
|
|
$
|
3,571
|
|
As of November 30, 2012, the convertible notes were reclassified
to demand notes given the maturity of the notes and demand for payment being made.
BioPower Operations Corporation and Subsidiaries
(A Development Stage Company)
Notes to Consolidated Financial Statements
November 30, 2012 and 2011
Note 9 Stockholders’ Deficit
On January 28, 2011, the Company issued
one share of Series A, preferred stock for $1. This series of preferred stock had a provision that the holder of the one share,
a related party controlled by the Company’s Chief Executive Officer and a Director, can vote 50.1% of the total votes. There
are no preferences, dividends, or conversion rights.
On September 13, 2010, the Company issued
10,000 shares of common stock to its founders for $1 ($0.0001/share). On January 5, 2011, in connection with the re-domiciling
to Nevada, these shares were cancelled for no consideration.
In 2011, the Company issued the following
shares for cash and services:
Type
|
|
Quantity
|
|
|
Valuation
|
|
|
Range of Value per share
|
|
Cash
|
|
|
40,330,000
|
|
|
$
|
318,910
|
|
|
$
|
0.0001
– 0.50
|
|
Cash – related parties
|
|
|
44,800,000
|
|
|
|
4,480
|
|
|
|
0.0001
|
|
License agreement (1)
|
|
|
1,000,000
|
|
|
|
250,000
|
|
|
|
0.25
|
|
Services rendered
(2)
|
|
|
4,150,000
|
|
|
|
50,000
|
|
|
|
0.012
|
|
Total
|
|
|
90,280,000
|
|
|
$
|
623,390
|
|
|
$
|
0.0001
- $0.50
|
|
(1) See Note 9(C)
(2) In connection with the stock issued
for services rendered, the Company determined fair value based upon the value of the services provided, which was the most readily
available evidence.
During the year ended November 30, 2012,
the Company authorized for issuance the following shares for cash and services:
Type
|
|
Quantity
|
|
|
Valuation
|
|
|
Range of Value
per share
|
|
Cash
|
|
|
200,000
|
|
|
$
|
50,000
|
|
|
$
|
0.25
|
|
Services rendered – related parties
|
|
|
50,000
|
|
|
|
11,000
|
|
|
|
0.22
|
|
Services rendered
|
|
|
150,000
|
|
|
|
97,500
|
|
|
|
0.65
|
|
Debt Conversion
|
|
|
200,000
|
|
|
|
50,000
|
|
|
|
0.25
|
|
Total (3)
|
|
|
600,000
|
|
|
$
|
208,500
|
|
|
|
$ 0.22-0.65
|
|
(3) The 600,000 shares are recorded as
a current liability, common stock payable because they have not been issued. Given these shares have not been issued, they are
not included in earnings per share for the year ended November 30, 2012.
(C) Stock issued for license
In connection with the license agreement,
the following occurred:
BioPower Operations Corporation and Subsidiaries
(A Development Stage Company)
Notes to Consolidated Financial Statements
November 30, 2012 and 2011
On January 27, 2011, an agreement was executed
with Green Oil Plantations Ltd. and their affiliates (“Green Oil”) for an exclusive license of fifty years in exchange
for 1,000,000 shares of common stock, having a fair value of $250,000 ($0.25/share), based upon recent cash offerings to third
parties, at that time, to utilize Green Oil’s licensed technologies and turnkey model for growing energy crops in North America,
South America, Central America and the Caribbean excluding Cuba.
On November 30, 2012, we determined that
the license was worthless because we could not get the technical information we needed to proceed with utilizing the license. Therefore,
we recorded an impairment loss of $240,795 as of November 30, 2012.
As of November 30, 2012 and 2011 the license
is summarized as follows:
|
|
2012
|
|
|
2011
|
|
License
|
|
$
|
250,000
|
|
|
$
|
250,000
|
|
Accumulated Amortization
|
|
|
(9,205
|
)
|
|
|
(4,205
|
)
|
Impairment
|
|
|
(240,795
|
)
|
|
|
-
|
|
License - Net
|
|
$
|
-
|
|
|
$
|
245,795
|
|
(D) Warrants
On January 11, 2011, the Company issued
1-year warrants for 1,000,000 shares with a consultant, with an exercise price of $1 per share. The warrants were granted for services
rendered. The warrants had a fair value of $60,800, based upon the Black-Scholes option-pricing model. The Company used the following
weighted average assumptions:
Expected dividends
|
|
|
0
|
%
|
Expected volatility
|
|
|
150
|
%
|
Expected term
|
|
|
1 year
|
|
Risk free interest rate
|
|
|
0.28
|
%
|
Expected forfeitures
|
|
|
0
|
%
|
BioPower Operations Corporation and Subsidiaries
(A Development Stage Company)
Notes to Consolidated Financial Statements
November 30, 2012 and 2011
|
|
|
|
|
|
|
|
Weighted Average
|
|
|
|
|
|
|
|
|
|
Weighted
|
|
|
Remaining
|
|
|
|
|
|
|
|
|
|
Average
|
|
|
Contractual
|
|
|
|
|
|
|
|
|
|
Exercise
|
|
|
Life in
|
|
|
Intrinsic
|
|
|
|
Warrants
|
|
|
Price
|
|
|
Years
|
|
|
Value
|
|
Balance - November 30, 2011
|
|
|
1,000,000
|
|
|
$
|
1.00
|
|
|
|
.12
|
|
|
|
|
|
Granted
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
Forfeited/Cancelled(1)
|
|
|
(1,000,000
|
)
|
|
|
-
|
|
|
|
|
|
|
|
|
|
Exercised
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
Balance – November 30, 2012-outstanding
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
|
|
-
|
|
Balance – November 30, 2012-exercisable
|
|
|
-
|
|
|
$
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
(1)
|
On January 11, 2012, the 1,000,000 warrants expired unexercised.
|
Note 10 Related Party Transactions
(A) License Agreement – Former
Affiliate of Chief Executive Officer
On November 30, 2010, the Company entered
into an exclusive license agreement with a company that is a former affiliate of the Company’s Chief Executive Officer. The
license gives the Company the right to utilize Intellectual Property rights (“IP”) and technology licenses to produce
high-density short rotation biomass energy crops on an exclusive basis in the United States, Central America, Mexico, and Guam
in perpetuity.
If the former affiliate company charges
a lesser percentage to another entity, then the first $50,000,000 will be decreased to the lowest percentage charged.
(B) Other related party transactions
The Company has separated accounts payable
and accrued expenses on the balance sheet and expenses on the statement of operations to reflect the expenses that pertain to related
parties primarily consisting of officer compensation, health insurance, interest on notes and reimbursable expenses to officers
for travel, meals and entertainment, vehicle and other related business expenses.
During the years ended November 30, 2012
and 2011, the Company recorded related party general and administrative expenses of $563,715 and $543,006, respectively, and related
party interest expense of $69,299 and $4,050, respectively.
Note 11 Formation of Subsidiaries
On January 14, 2011, the Company formed
Global Energy Crops Corporation (“GECC”), a 100% wholly owned subsidiary. GECC intends to:
|
-
|
Seek financing from US aid and similar organizations for energy crop growing projects in third
world countries for the conversion to electricity and biofuels,
|
|
-
|
Joint venture with both international and smaller technology companies who are currently producing
electricity and biofuels wherein GECC intends to provide biomass feedstock, and
|
|
-
|
Execute supply chain contracts with major buyers of energy crop products including electricity
and biofuels.
|
BioPower Operations Corporation and Subsidiaries
(A Development Stage Company)
Notes to Consolidated Financial Statements
November 30, 2012 and 2011
On May 12, 2012 the company formed FTZ
Energy Exchange Corporation, a 100% wholly owned subsidiary.
On August 2, 2012 the Company formed Agribopo,
Inc., a 100% wholly-owned subsidiary for the development of biomass related projects.
All of the above subsidiaries other than
GECC are currently inactive except for their formation. Global Energy Crops Corporations signed the license agreement with AGT
Technologies LLC.
Note 12 Commitments and Contingencies
Commitments
(A) Employment Agreements – Officers
and Directors
As of November 30, 2012, the Company had
employment agreements with certain officers and directors (two individuals) containing the following provisions:
Term of contract
|
5 years
|
Salary
|
$125,000 - $200,000
|
Salary deferral
|
All salaries will be accrued until the Company has raised $2,500,000.
|
(B) Lease Agreement
On March 18, 2011, the Company entered
into a 26-month lease that commenced on April 1, 2011 and will expire on May 31, 2013. The Company’s monthly lease payment
of $4,150 commenced on July 1, 2011. The Company recognizes rent expense on a straight-line basis over the occupancy period.
Rent expense was $44,058 and $29,372 for
the year ended November 30, 2012 and 2011, respectively.
Deferred rent payable (component of accounts
payable and accrued expenses) at November 30, 2012 and 2011 was $2,874 and $8,620, respectively. Deferred rent payable is
the sum of the difference between the monthly rent payment and the monthly rent expense of an operating lease that contains escalated
payments in future periods.
(C) Consulting Agreements
On January 5, 2012, the Company entered
into a consulting agreement for financing. The Company paid a retainer fee of $15,000 by agreeing to issue 60,000 shares of restricted
common stock at $0.25 per share. The fair value of the Company’s common stock was based upon third party cash offerings at
that time. The Company expensed this issuance as a component of general and administrative expenses. The consultant failed
to honor the commitments in the agreement. On May 18, 2012, the Company reversed the expense and the shares were cancelled.
BioPower Operations Corporation and Subsidiaries
(A Development Stage Company)
Notes to Consolidated Financial Statements
November 30, 2012 and 2011
On March 26, 2012, the Company entered
into a consulting agreement to provide various investment banking services including putting together business models for project
finance and introducing the Company to potential lenders for a castor project. The Company paid a fee of 150,000 shares of common
stock, having a fair value of $97,500 ($0.65/share), based upon the quoted closing trading price. During the year ended November
30, 2012, the Company expensed this issuance as a component of general and administrative expenses. These shares have not been
issued, are included in common stock payable and are not included in earnings per share calculations as of November 30, 2012.
Note 13 Other Income - Consulting Revenue
On February 13, 2012, the Company was engaged
by a third party to provide consulting services in a three year contract for $60,000 per year plus a non-refundable $60,000 initial
payment upon execution. The Company may earn fees in the form of cash or common stock of the third party, a public company, at
their election. In lieu of cash payments for services to be rendered under the terms of the agreement, the third party elected
to pay the Company 15,000,000 shares of public company restricted common stock, at a fifty percent discount using the preceding
five days average trading price per the terms of the agreement. $120,000 was due upon execution of agreement. The fair value of
the shares received upon the execution of this agreement was $253,500, as evidenced by the quoted closing trading price. The Company
recorded the value of the shares received as deferred revenue totaling $120,000 which evidenced the fair value of the services
to be performed and recorded a gain of $133,500, with a corresponding asset classified as available for sale securities. A gain
was recorded since the value of the shares received was greater than the value of the services to be rendered upon the execution
of the agreement.
In August 2012, the Company executed a
loan agreement with a lender, who is also a shareholder, to obtain 10,000,000 free trading shares of the public company The shares
received were sold during 2012. In exchange for the free trading shares, the Company was required to repay 10,500,000 shares in
free trading stock of this public company. The 500,000 shares are deemed to be a loan cost, having a fair value of $6,250 ($0.0125/share),
based upon the quoted closing trading price on the date of the agreement.
During 2012, the Company, received 15,000,000
shares of the public company for services to be rendered and sold 10,000,000 shares as noted above based upon the ability to obtain
the 10,000,000 shares of free trading stock from the lender. The 15,000,000 shares is currently held in escrow of which 4,500,000
shares will be released to the Company and the balance of the 10,500,000 shares will be paid to the shareholder for the 10,000,000
shares borrowed and the 500,000 shares for the loan cost as noted above upon the shares becoming unrestricted. The Company does
not have any rights to the 10,500,000 shares. The Company has not recorded any asset or liability for the shares held in escrow.
● $60,000 is due on February 13,
2013; and
● $60,000 is due on February 13,
2014
As of November 30, 2012, the Company recorded
consulting revenue of $63,571 and deferred revenue of $56,429, consisting of short term deferred revenue of $31,429 and long term
deferred revenue of $25,000.
See Note 3 for reconciliation of amounts
associated with the purchase and sale of certain AFS securities.
Note 14 License Agreement
On November 27, 2012, the Company entered
into a non-exclusive global License from AGT Technologies LLC until June 2029 when the patent expires. The license is for the patented
one-step enzyme technology which converts wastes from poultry, hogs, humans and sugar to cellulosic ethanol, fertilizer and other
products. We would pay our Licensor 50% of any sub-license fees that we receive. We also would pay our Licensor 12% of all royalties
on all revenues we earn from utilizing the technology. This 12% is calculated on the basis of net gross revenues which equal gross
revenues less all direct costs associated with the production of the revenues. Once we order a facility we have 120 days to pay
$300,000 for the enzymes.
BioPower Operations Corporation and Subsidiaries
(A Development Stage Company)
Notes to Consolidated Financial Statements
November 30, 2012 and 2011
Note 15 Fair Value of Financial Assets
and Liabilities
The Company measures assets and liabilities
at fair value based on an expected exit price as defined by the authoritative guidance on fair value measurements, which represents
the amount that would be received on the sale of an asset or paid to transfer a liability, as the case may be, in an orderly transaction
between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset
or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value
on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level. The
following are the hierarchical levels of inputs to measure fair value:
• Level
1: Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.
• Level
2: Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets
or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs
that are derived principally from or corroborated by observable market data by correlation or other means.
• Level
3: Unobservable inputs reflecting the Company’s assumptions incorporated in valuation techniques used to determine fair value.
These assumptions are required to be consistent with market participant assumptions that are reasonably available.
The Company has assets measured at fair
market value on a recurring basis. Consequently, the Company had gains and losses reported in the statement of comprehensive income
(loss), that were attributable to the change in unrealized gains or losses relating to those assets and liabilities still held
at the reporting date for the period ended November 30, 2012.
The following is the Company’s assets
measured at fair value at November 30, 2012 and 2011:
|
|
2012
|
|
|
2011
|
|
Level 1 – None
|
|
$
|
-
|
|
|
$
|
-
|
|
Level 2 – Marketable Securities (AFS)
|
|
|
38,250
|
|
|
|
-
|
|
Level 3 – None
|
|
|
-
|
|
|
|
-
|
|
Total
|
|
$
|
38,250
|
|
|
$
|
-
|
|
BioPower Operations Corporation and Subsidiaries
(A Development Stage Company)
Notes to Consolidated Financial Statements
November 30, 2012 and 2011
The carrying amounts reported in the balance
sheet for available for sale securities, prepaid expenses, accounts payable and accrued expenses, accounts payable and accrued
expenses – related parties, notes payable, notes payable – related parties, convertible debt and convertible debt –
related party, approximate fair value based on the short-term nature of these instruments.
Note 16 Subsequent Events
On February 5, 2013 the Company entered
in an investor relations agreement for a period of one year covering financial and public relations activities including conception
and implementation relating to our corporate and business development plan and assist in corporate communications, press releases
and presentations. The contract can be cancelled after three months on a quarterly basis. The Company has agreed to pay 800,000
restricted shares of common stock per quarter and $3,000 per month in cash or stock. The initial payment was for 256,250 shares
covering the first quarter of the contract.
During March, 2013, a third party investor
advanced $125,000. The loan bears interest at 8%, is unsecured and due on demand.